Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), drawn from the whole corpus: 13 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Cure rates for locally advanced HPV-negative disease have barely moved in twenty years.
No predictive biomarker beyond PD-L1, which is imperfect.
Function after laryngectomy, glossectomy and high-dose radiotherapy.
Second primaries and continued smoking after treatment.
Incidence still rising where tobacco and areca nut use are common.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 19 changes by month →When this page itself was last checked or edited.
Median EFS 59.
Three-year disease-free survival 63.
A milestone in how this cancer is treated.
EFS 19.
A milestone in how this cancer is treated.